16 recruiting, 15 active not recruiting, 12 completed, 6 terminated. 28 Phase 2, 11 Phase 3, 8 Not applicable, 7 Phase 1, 1 Early Phase 1.
Follow Androgen Deprivation Therapy: new trials by email Literature Review of Androgen Deprivation Therapy trials Research Report on Androgen Deprivation Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-31 | 2026-09-04 |
| Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection - Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 60 | 2025-11-05 | 2026-08-17 |
| EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | University of Virginia | 60 | 2025-01-30 | 2026-04-27 |
| A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Relacorilant, Enzalutamide, Placebo (Sugar Pill) - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Chicago | 90 | 2025-01-06 | 2026-08-31 |
| Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging Darolutamide 300 mg, Stereotactic body radiation therapy, Androgen deprivation therapy - Prostatic Cancer, Castration-Resistant | Phase 3 | Recruiting | UNICANCER | 336 | 2024-10-07 | 2024-12-20 |
| PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. Apalutamide, Androgen Deprivation Therapy - Androgen Axis Suppression, Prostatectomy | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 120 | 2024-09-10 | 2026-07-22 |
| Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer. Dalpicilib, Abiraterone Acetate (II), Androgen Deprivation Therapy - The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer | Phase 2 | Not yet recruiting | Qilu Hospital of Shandong University | 43 | 2024-07-31 | 2024-07-15 |
| PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Miami | 34 | 2024-07-03 | 2026-06-16 |
| Implementation of Precision Medicine in High-risk Prostate Cancer High-risk treatment SOC, Active monitoring, Radical prostatectomy - Prostate Cancer | Recruiting | Andreas Josefsson | 5500 | 2024-06-10 | 2025-09-03 | |
| Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment Radiation, Radiation SBRT only, ADT - Prostate Cancer | Phase 3 | Recruiting | Canadian Cancer Trials Group | 710 | 2024-04-25 | 2026-04-14 |
| SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Phase 3 | Active not recruiting | Mayo Clinic | 118 | 2024-04-04 | 2026-09-17 |
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial Antiandrogen Therapy, Bone Scan, Computed Tomography - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2024-02-18 | 2026-10-08 |
| Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life Radiation, MRI, Androgen Deprivation Therapy - Prostate Cancer | Not applicable | Recruiting | University of Chicago | 60 | 2024-01-05 | 2026-03-04 |
| ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer Actinium-J591, Stereotactic Body Radiation Therapy, Androgen Deprivation Therapy - Prostate Cancer Metastatic | Phase 1 | Withdrawn | Weill Medical College of Cornell University | 2023-12-01 | 2023-08-24 | |
| Dose Escalation For INtraprostatic LEsions Prostate SBRT with Focal Boost, Triptorelin Injection - Prostatic Neoplasms | Phase 2 | Recruiting | Ottawa Hospital Research Institute | 54 | 2023-11-23 | 2024-01-05 |
| Pembro With Radiation With or Without Olaparib Pembrolizumab, Olaparib, Androgen Deprivation Therapy - Prostate Cancer | Phase 2 | Recruiting | Zin W Myint | 64 | 2023-07-27 | 2026-07-14 |
| Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment apalutamide, androgen deprivation therapy, cytoreductive radical prostatectomy with/without pelvic lymph node dissection - Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer | Phase 2 | Not yet recruiting | Fudan University | 47 | 2023-05-01 | 2023-02-08 |
| Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy, Androgen deprivation therapy - Recurrent Prostate Cancer | Not applicable | Active not recruiting | Insel Gruppe AG, University Hospital Bern | 36 | 2023-03-29 | 2025-12-31 |
| Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy - Prostate Cancer | Early Phase 1 | Active not recruiting | University of Wisconsin, Madison | 30 | 2023-03-08 | 2026-06-02 |
| Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy - Prostate Cancer, Cancer of the Prostate | Not applicable | Active not recruiting | Washington University School of Medicine | 28 | 2023-01-18 | 2026-07-02 |
Showing 20 of 58. Sign in to see all of them.
Prostatic Neoplasms (47) · Neoplasm Metastasis (4) · Insulin Resistance (1) · Lymphatic Metastasis (1) · Neoplasms (1) · Prostatic Diseases (1) · Prostatic Neoplasms, Castration-Resistant (1)
Fudan University (3) · M.D. Anderson Cancer Center (3) · UNICANCER (3) · Jonsson Comprehensive Cancer Center (2) · University of Chicago (2) · Alliance for Clinical Trials in Oncology (1) · Andreas Josefsson (1) · Andrew McDonald (1) · Astellas Pharma Inc (1) · Barbara Ann Karmanos Cancer Institute (1) · Canadian Cancer Trials Group (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · David VanderWeele (1) · Duke University (1)
United States (34) · China (7) · Sweden (5) · Switzerland (5) · Belgium (4) · Canada (4) · France (3) · Italy (3) · Spain (3) · Australia (2) · Ireland (2) · Japan (2) · Netherlands (2) · Norway (2) · Romania (2)
Amado J Zurita Saavedra (1) · Amar Kishan (1) · Amar Kishan, MD (1) · Amit Bhatt, M.D., Ph.D. (1) · Andreas Josefsson, MD, PhD (1) · Andrew Loblaw (1) · Andrew McDonald, MD (1) · B van Triest, MD, PhD (1) · Benjamin J Rich, MD (1) · Benjamin Maughan, MD (1) · Carlos E. Vargas, MD (1) · Chris Luminais, MD (1) · Christos Kyriakopoulos (1) · Dana Rathkopf, MD (1)
PMID 33270906, PMID 18990168, PMID 22452894, PMID 22747660, PMID 24590644, PMID 26718929, PMID 26719232, PMID 28300506, PMID 28578639, PMID 29529169, PMID 30355464, PMID 31560068, PMID 32398040, PMID 32651467, PMID 32994091, PMID 33386290, PMID 33599706, PMID 33744986, PMID 34350976, PMID 34757812, PMID 34953525, PMID 34961659, PMID 35273377, PMID 35405085, PMID 35671327, PMID 35715340, PMID 36059000, PMID 36503429, PMID 36934894, PMID 37142371, PMID 37821242, PMID 37973477, PMID 38296279, PMID 38421252, PMID 38796422, PMID 39151419, PMID 39751962, PMID 39923274, PMID 39924002, PMID 40339593, PMID 40372727, PMID 40467357, PMID 40539499, PMID 40639383, PMID 40645505, PMID 41880608, PMID 41882599, PMID 42061373, PMID 42252348
2004 (1), 2023 (1), P30CA022453 (1), P30CA033572 (1), P30CA060553 (1), P30CA072720 (1), P50CA097186 (1), R21CA259808 (1), U10CA031946 (1), U10CA180820 (1)